<< Back to News

System Formulary Update
Lifileucel (Amtagvi)

Situation:

Lifileucel (Amtagvi) frozen suspension of tumor-derived T cells in 5% DMSO, 0.5% albumin, & 300 IU/mL IL-2 for injection was approved for addition to the health system formulary at the May 2024 System Pharmacy & Therapeutics Committee meeting.

Background:

The following medication was reviewed: Lifileucel (Amtagvi) frozen suspension of tumor-derived T cells in 5% DMSO, 0.5% albumin, & 300 IU/mL IL-2 for injection

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Lifileucel (Amtagvi) frozen suspension of tumor-derived T cells in 5% DMSO, 0.5% albumin, & 300 IU/mL IL-2 for injection

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, August 27, 2024